Table 1.
Clinical characteristics of all study subjects
Variable, n (%) | |
---|---|
Age, median (year) | 64 (52–74) |
Gender | |
Male | 26 (83.9) |
Female | 5 (16.1) |
Smoking status | |
Smoker/ex‐smoker | 23 (74.2) |
Never smoker | 8 (25.8) |
ECOG PS | |
0 | 25 (80.7) |
1 | 5 (16.1) |
2 | 1 (3.2) |
Histology | |
Adenocarcinoma | 20 (64.5) |
Squamous cell carcinoma | 8 (25.8) |
NSCLC NOS | 3 (9.7) |
Staging | |
IIIA | 8 (25.8) |
IIIB | 21 (67.7) |
IIIC | 2 (6.5) |
EGFR mutation status | |
Mutated EGFR | 4 (12.9) |
Wild type | 19 (61.3) |
Unknown | 8 (25.8) |
ALK fusion status | |
Positive | 1 (3.3) |
Negative | 17 (54.8) |
Unknown | 13 (41.9) |
PD‐L1 TPS | |
Positive (≥1%) | 14 (45.2) |
Negative (<1%) | 6 (19.3) |
Unknown | 11 (35.5) |
Chemotherapy regimen | |
Docetaxel plus cisplatin | 13 (41.9) |
Vinorelbine plus cisplatin | 18 (58.1) |
Dose of radiotherapy | |
60–66 Gy | 23 (74.2) |
>66 Gy | 8 (25.8) |
Timing of durvalumab initiation post‐CCRT, median (month) | 2.8 (1.8–3.7) |
Total | 31 (100.0) |
ALK, anaplastic lymphoma kinase; CCRT, concurrent chemoradiation; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; PD‐L1, Programmed death‐ligand 1; TPS, tumor proportion score.